Talaris Therapeutics (Nasdaq:TALS) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

TALS Aktienübersicht

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States.

TALS fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	0/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Belohnungen

Risikoanalyse

Die Erträge sind in den letzten 5 Jahren um 40.8% pro Jahr zurückgegangen

Erzielt weniger als 1 Million USD an Einnahmen ($0)

Die Aktionäre wurden im vergangenen Jahr erheblich verwässert

Talaris Therapeutics, Inc. Wettbewerber

ALX Oncology Holdings

NasdaqGS:ALXO

US$553.8m

Celcuity

NasdaqCM:CELC

US$554.6m

Lexeo Therapeutics

NasdaqGM:LXEO

US$547.9m

Frequency Therapeutics

NasdaqCM:FREQ

US$547.3m

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Talaris Therapeutics
Historical stock prices
Current Share Price	US$27.20
52 Week High	US$32.90
52 Week Low	US$8.90
Beta	2.18
1 Month Change	-5.88%
3 Month Change	-11.69%
1 Year Change	91.55%
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	-83.26%

Aktuelle Nachrichten und Updates

Recent updates

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Jun 30

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Mar 23

Talaris Therapeutics EPS beats by $0.49

Jun 14

Aktionärsrenditen

	TALS	US Biotechs	US Markt
7D	-4.9%	-0.4%	-0.6%
1Y	91.5%	5.4%	22.5%

Rendite im Vergleich zur Industrie: TALS übertraf die Branche US Biotechs, die im vergangenen Jahr eine Rendite von 7.4 erzielte.

Rendite vs. Markt: TALS übertraf den Markt US, der im vergangenen Jahr eine Rendite von 25.6 erzielte.

Preisvolatilität

Is TALS's price volatile compared to industry and market?
TALS volatility
TALS Average Weekly Movement	5.6%
Biotechs Industry Average Movement	10.7%
Market Average Movement	5.8%
10% most volatile stocks in US Market	15.7%
10% least volatile stocks in US Market	2.9%

Stabiler Aktienkurs: TALS hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: TALSDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1988	84	Mary Fenton	talaristx.com

Talaris Therapeutics, Inc.'s Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Talaris Therapeutics im Vergleich zum Marktanteil des Unternehmens?
TALS grundlegende Statistiken
Marktanteil	US$553.16m
Gewinn(TTM)	-US$74.77m
Umsatz(TTM)	n/a

0.0x

Kurs-Umsatz-Verhältnis

-7.4x

Kurs-Gewinn-Verhältnis

Ist TALS zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
TALS Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$0
Kosten der Einnahmen	US$0
Bruttogewinn	US$0
Sonstige Ausgaben	US$74.77m
Umsatz	-US$74.77m

Zuletzt gemeldete Gewinne

Jun 30, 2023

Datum des nächsten Gewinnberichts

k.A.

Gewinn per Aktie (EPS)	-3.68
Bruttomarge	0.00%
Nettogewinnspanne	0.00%
Schulden/Eigenkapital-Verhältnis	0%

Wie hat sich TALS auf lange Sicht entwickelt?

Historische Performance und Vergleiche

TALS Aktienübersicht

Belohnungen

Risikoanalyse

Talaris Therapeutics, Inc. Wettbewerber

NasdaqGS:ALXO

US$553.8m

NasdaqCM:CELC

US$554.6m

NasdaqGM:LXEO

US$547.9m

NasdaqCM:FREQ

US$547.3m

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

New major risk - Shareholder dilution

New minor risk - Market cap size

Talaris Therapeutics, Inc. Announces Special Dividend

Talaris Therapeutics, Inc. Announces Special Dividend

Price target increased by 39% to US$12.50

Recent updates

Tourmaline Bio, Inc. completed the acquisition of Talaris Therapeutics, Inc. (NasdaqGM:TALS) from a group of shareholders in a reverse merger transaction.

New major risk - Shareholder dilution

New minor risk - Market cap size

Talaris Therapeutics, Inc. Announces Special Dividend

Talaris Therapeutics, Inc. Announces Special Dividend

Price target increased by 39% to US$12.50

Tourmaline Bio, Inc. entered into a definitive agreement to acquire Talaris Therapeutics, Inc. (NasdaqGM:TALS) from shareholders in a reverse merger transaction.

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Founder recently sold US$80k worth of stock

Founder notifies of intention to sell stock

Talaris Therapeutics, Inc. Appoints Mary Kay Fenton as President

Will Talaris Therapeutics (NASDAQ:TALS) Spend Its Cash Wisely?

Price target decreased by 17% to US$7.50

Founder recently sold US$319k worth of stock

Price target decreased by 17% to US$7.50

Price target increased by 11% to US$10.00

Founder notifies of intention to sell stock

Price target decreased by 12% to US$8.40

Talaris Therapeutics, Inc. Announces Plans to Explore Strategic Alternatives and Implements Restructuring Plan

Is Talaris Therapeutics (NASDAQ:TALS) In A Good Position To Invest In Growth?

Price target decreased to US$9.60

Talaris Therapeutics, Inc. Presents Data on Mechanisms of Fcr001 Activity to Induce Immune Tolerance

Price target increased to US$16.75

Talaris Therapeutics Provides Update on Freedom-1 Phase 3 Clinical Trial

We're Keeping An Eye On Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Talaris drops 24% after patient death in late-stage trial for lead asset

Talaris Therapeutics: Plenty Of Upside Remains, But So Does The Risk

Member of Scientific Advisory Board notifies of intention to sell stock

Talaris Therapeutics GAAP EPS of -$0.44

President recently bought US$167k worth of stock

Independent Chairman recently bought US$500k worth of stock

We're Not Very Worried About Talaris Therapeutics' (NASDAQ:TALS) Cash Burn Rate

Price target decreased to US$15.25

Talaris Therapeutics Provides Freedom-1 Phase 3 Clinical Update

Talaris Therapeutics achieves positive results in phase 3 kidney transplant drug trial

Talaris Therapeutics, Inc.(NasdaqGM:TALS) dropped from Russell 2000 Growth Index

Talaris Therapeutics Presents Additional Phase 2 Data and Analyses At American Transplant Congress 2022

Talaris Therapeutics, Inc. Announces Board Changes

Talaris Therapeutics, Inc., Annual General Meeting, Jun 09, 2022

Talaris Therapeutics, Inc Shares New Data on COVID-19 Outcomes Among Living Donor Kidney Transplant Patients Treated in its Phase 2 Trial of Investigational Cell Therapy Product FCR001 (NCT00497926)

Talaris Therapeutics (NASDAQ:TALS) Is In A Good Position To Deliver On Growth Plans

Talaris Therapeutics, Inc. Presents High-Resolution Analysis of HLS Mismatching in Phase 2 Trial in Living Donor Kidney Transplant

Talaris Therapeutics EPS beats by $0.49

Talaris Therapeutics, Inc. has completed an IPO in the amount of $150.025 million.

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Talaris Therapeutics, Inc.'s Grundlagenzusammenfassung

0.0x

-7.4x

Erträge &amp; Einnahmen

Erträge & Einnahmen